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ABSTRACT
The human Ena/Vasp-like (EVL) protein is con-
sidered to be a bifunctional protein, involved in
both actin remodeling and homologous recombin-
ation. In the present study, we found that human
EVL forms heat-stable multimers of circular
single-stranded DNA (ssDNA) molecules in the
presence of a type I topoisomerase in vitro.A n
electron microscopic analysis revealed that the
heat-stable ssDNA multimers formed by EVL and
topoisomerase were ssDNA catemers. The ssDNA
catenation did not occur when either EVL or topo-
isomerase was omitted from the reaction mixture.
A deletion analysis revealed that the ssDNA caten-
ation completely depended on the annealing activity
of EVL. Human EVL was captured from a human cell
extract by TOPO IIIa-conjugated beads, and the
interaction between EVL and TOPO IIIa was con-
firmed by a surface plasmon resonance analysis.
Purified TOPO IIIa catalyzed the ssDNA catenation
with EVL as efficiently as the Escherichia coli topo-
isomerase I. Since the ssDNA cutting and rejoining
reactions, which are the sub-steps of ssDNA caten-
ation, may be an essential process in homologous
recombination, EVL and TOPO IIIa may function in
the processing of DNA intermediates formed during
homologous recombination.
INTRODUCTION
Human Ena/Vasp-like (EVL) is a member of the ENA/
VASP family, which is involved in actin-remodeling
processes (1). We previously reported (2) that EVL may
also function in homologous recombination, because it
directly binds to RAD51 and RAD51B, which are essen-
tial proteins for meiotic homologous recombination and
mitotic recombinational repair of DNA double-strand
breaks (3–6). Biochemical studies revealed that EVL
forms tetramer-based multimers, and actually stimulates
the RAD51-mediated recombinase reactions, such as
homologous pairing and strand exchange, in vitro (2,7).
In addition to the RAD51-stimulating activity, EVL
also possesses ssDNA annealing activity (2), which is
considered to be important for the homologous-
recombination processes. Therefore, EVL may have dual
functions in cytoplasmic actin remodeling and nuclear
homologous recombination.
Topoisomerases promote DNA strand cutting and re-
joining, and are known to be important in homologous
recombination. Escherichia coli RecA, a bacterial
homolog of RAD51, forms homologous joint molecules
between circular ssDNA and closed circular dsDNA by its
recombinase activity (8). Escherichia coli topoisomerase I
(Topo I) reportedly converts the homologous joint mol-
ecules formed by RecA into hemicatemers (8). Escherichia
coli topoisomerase III efﬁciently catenates closed circular
dsDNAs in the presence of RecQ helicase (9,10), which is
suggested to function in homologous recombination. In
humans, TOPO IIIa forms a complex with BLM and
BLAP75 (11,12), and the complex is reportedly involved
in the dissolution of the Holliday junction (13–18), which
is a DNA intermediate formed in the late stage of hom-
ologous recombination. These facts suggest that the DNA
cutting and rejoining activities of topoisomerases play im-
portant roles in homologous recombination.
In the present study, we unexpectedly found that EVL,
with either E. coli Topo I or human TOPO IIIa, catalyzed
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isomerase quenched the ssDNA-catenating reaction,
indicating that both proteins are essential for this
reaction. A deletion analysis revealed that the EVL
C-terminal domain, which possesses the annealing
activity, is responsible for the ssDNA catenation. We
also found that EVL physically interacted with human
TOPO IIIa in a human cell extract and in vitro. These
new ﬁndings suggest that EVL may function with a type
I topoisomerase, such as TOPO IIIa, by catalyzing
ssDNA cutting and re-joining reactions in the conversion
of DNA intermediates during homologous recombination.
MATERIALS AND METHODS
Protein preparation
Human EVL, EVL(1–221) and EVL(222–418) were
prepared by the methods described earlier (2,7). In these
methods, human EVL, EVL(1–221) and EVL(222–418)
were expressed as His6-tagged proteins, and the His6 tag
was removed by a thrombin treatment during the puriﬁ-
cation procedure. Human RPA was produced in E. coli
cells and was prepared according to the published
protocol (19).
The DNA fragment encoding human TOPO IIIa was
isolated from a human cDNA pool (purchased from
Clontech Laboratories, Mountain View, CA, USA) by
the polymerase chain reaction. The TOPO IIIa DNA
fragment was cloned in the NdeI site of the pET15b
vector (Novagen, Darmstadt, Germany). In this construct,
the His6 tag sequence was fused to the N terminus of the
protein. Human TOPO IIIa was produced in the E. coli
BL21(DE3) codon plus-RP strain (Stratagene, La Jolla,
CA, USA) and was puriﬁed by the following procedure.
The cells producing His6-tagged TOPO IIIa were resus-
pended in a 50mM Tris–HCl buffer (pH 7.5), containing
1M NaCl, 5mM 2-mercaptoethanol and 10% glycerol,
and were disrupted by sonication. The cell debris was
removed by centrifugation for 20min at 30000g, and the
lysate was mixed gently by the batch method with
Ni-NTA agarose beads (3ml, Qiagen, Hilden, Germany)
at 4C for 1h. The His6-tagged TOPO IIIa-bound beads
were washed with 40ml of 20mM potassium phosphate
buffer (pH 7.4), containing 500mM NaCl, 5mM
2-mercaptoethanol, 40mM imidazole and 10% glycerol,
and then were washed again with 40ml of 20mM potas-
sium phosphate buffer (pH 7.4), containing 500mM
NaCl, 5mM 2-mercaptoethanol, 30mM imidazole and
10% glycerol. The beads were then packed into an
Econo-column (Bio-Rad Laboratories, Hercules, CA,
USA) and were washed with 90ml of 20mM potassium
phosphate buffer (pH 7.4), containing 500mM NaCl,
5mM 2-mercaptoethanol, 30mM imidazole and 10%
glycerol. His6-tagged TOPO IIIa was eluted with a
linear gradient of 30–300mM imidazole (13-column
volumes), in 20mM potassium phosphate (pH 7.4),
100mM NaCl, 5mM 2-mercaptoethanol and 10%
glycerol. Peak fractions containing His6-tagged TOPO
IIIa were diluted 5-fold with a 20mM potassium
phosphate buffer (pH 7.4), containing 5mM
2-mercaptoethanol and 10% glycerol and were mixed
gently by the batch method with Hydroxyapatite resin
(5ml, Bio-Rad Laboratories) at 4C for 1h. The
unbound fraction was then dialyzed against a 20mM po-
tassium phosphate buffer (pH 7.4), containing 100mM
NaCl, 5mM 2-mercaptoethanol and 10% glycerol. After
the dialysis, the sample was loaded on an SP Sepharose
column (1ml, GE Healthcare Biosciences, Uppsala,
Sweden), which was equilibrated with 20ml of 20mM po-
tassium phosphate buffer (pH 7.4), containing 100mM
NaCl, 5mM 2-mercaptoethanol and 10% glycerol. The
resin was washed with 20ml of 20mM potassium phos-
phate buffer (pH 7.4), containing 225mM NaCl, 5mM
2-mercaptoethanol and 10% glycerol, and the His6-
tagged TOPO IIIa was then eluted with a linear gradient
of 225–600mM NaCl (24-column volumes). The puriﬁed
His6-tagged TOPO IIIa was dialyzed against 20mM
HEPES–NaOH buffer (pH 7.5), containing 100mM
NaCl, 5mM 2-mercaptoethanol and 20% glycerol, and
was stored at 80C. The concentration of the puriﬁed
His6-tagged TOPO IIIa was determined by the Bradford
method (20), using bovine serum albumin as the standard.
Assays for DNA binding
The fX174 circular ssDNA (20mM) was mixed with EVL
in 10ml of a standard reaction solution, containing 36mM
HEPES–NaOH (pH 7.5), 1mM dithiothreitol, 4mM
2-mercaptoethanol, 80mM NaCl, 1mM MgCl2, 24%
glycerol and 0.1mg/ml bovine serum albumin. The
reaction mixtures were incubated at 37C for 15min,
and were then analyzed by 0.8% agarose gel electrophor-
esis in 1 TAE buffer (40mM Tris–acetate and 1mM
EDTA) at 3.3V/cm for 2h. The bands were visualized
by ethidium bromide staining.
ssDNA-catenating assay
The fX174 circular ssDNA (20mM) was incubated with
EVL and Topo I (New England Biolabs, Ipswich,
MA, USA), in a reaction buffer containing 24mM
HEPES–NaOH (pH 7.5), 1mM MgCl2, 1mM Tris–HCl
(pH 7.5), 1.1mM dithiothreitol, 1mM 2-mercaptoethanol,
20mM NaCl, 5mM KCl, 3.5mM ammonium sulfate,
0.01mM EDTA, 11% glycerol and 0.1mg/ml bovine
serum albumin, at 37C for 1h. For the experiments
with TOPO IIIa, the reactions were conducted in a
buffer containing 30mM HEPES–NaOH (pH 7.5),
1mM MgCl2, 1mM dithiothreitol, 2.5mM
2-mercaptoethanol, 70mM NaCl, 14% glycerol and
0.1mg/ml bovine serum albumin. The samples were then
deproteinized by a treatment with 0.2% SDS and 1.3mg/
ml proteinase K at 37C for 15min. The products were
then incubated at 100C for 5min and were chilled on ice
for 5min. The products were separated by 1% agarose gel
electrophoresis, and the bands were visualized by SYBR
Gold (Invitrogen, Carlsbad, CA, USA) staining.
ssDNA-annealing assay
The ssDNA-annealing assay was performed as described
earlier (2). Brieﬂy, the ssDNA oligonucleotide 49-mer
(0.2mM) was incubated with the indicated amounts of
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reaction buffer, containing 28mM HEPES–NaOH
(pH 7.5), 50mM NaCl, 2mM 2-mercaptoethanol, 12%
glycerol, 0.1mM MgCl2, 1mM DTT and 0.1mg/ml
bovine serum albumin. The reactions were initiated by
the addition of 0.2mM antisense
32P-labeled 49-mer oligo-
nucleotide. At the times indicated, the reactions were
quenched with an excess of the unlabeled 49-mer oligo-
nucleotide. The DNA substrates and products were
deproteinized by a treatment with 0.2% SDS and 1.5mg/
ml proteinase K at 30C for 10min. The products were
fractionated by 10% PAGE in 0.5 TBE. The gels were
dried, exposed to an imaging plate and visualized using an
FLA-7000 imaging analyzer (Fujiﬁlm, Tokyo, Japan).
Electron microscopic analysis
The ssDNA catemers formed by EVL and Topo I were
extracted by phenol/chloroform and precipitated with
ethanol. The ssDNA catemers were then coated with
RecA in the absence of ATP and were stained on a
copper-plated carbon grid with 2% uranyl acetate. The
samples were visualized by tungsten rotary shadowing,
and were observed with a JEOL JEM 2000FX electron
microscope (JEOL, Akishima, Tokyo, Japan).
Pull-down assays with TOPO IIIa-conjugated beads
Puriﬁed human TOPO IIIa was covalently conjugated to
Afﬁ-Gel 10 beads (100ml, Bio-Rad), according to the
manufacturer’s instructions. To block the remaining
active ester sites, ethanolamine (pH 8.0) was added to a
ﬁnal concentration of 100mM, and the resin was
incubated at 4C overnight. The unbound proteins were
removed by washing the Afﬁ-Gel 10-TOPO IIIa beads
three times with 500ml of binding buffer, which contained
20mM HEPES–NaOH (pH 7.5), 300mM NaCl, 5mM
2-mercaptoethanol, 20% glycerol and 0.05% Triton
X-100. After washing the resin, the Afﬁ-Gel 10-protein
matrices were adjusted to 50% slurries, and were stored
at 4C. The control beads were made by the same method,
except that the TOPO IIIa was replaced by the TOPO IIIa
storage buffer. For the EVL-binding assay, the TOPO
IIIa-beads were incubated with an MCF7 whole-cell
extract (1.8mg of protein), and the beads were washed
three times with 200ml of washing buffer, containing
50mM Tris–HCl (pH 7.5), 100mM NaCl, 5mM EDTA,
0.5% NP-40, 1mM phenylmethylsulfonyl ﬂuoride and
protease inhibitor cocktail (Nacalai Tesque, Kyoto,
Japan). The proteins that copelleted with the TOPO IIIa
beads were fractionated by 7.5% SDS–PAGE. The EVL
protein was detected with the EVL-speciﬁc rabbit
polyclonal antibodies.
Surface plasmon resonance analysis
The surface plasmon resonance (SPR) signals were
measured with a Biacore X100 instrument (GE
Healthcare Biosciences, Uppsala, Sweden). Flow cells
were maintained at 25C during the measurement, and
the instrument was operated at the mid-ﬂow rate (30ml/
min). Puriﬁed EVL was conjugated to the activated surface
of the CM5 sensor chip (GE Healthcare Biosciences,
Uppsala, Sweden), using the standard amine coupling
conditions recommended by the manufacturer. The level
of the conjugated EVL protein was 5600 resonance units.
The SPR signals of the ﬂow cell containing a sensor chip
without the proteins were subtracted from those of
the SPR signals of the ﬂow cell containing the
EVL-conjugated sensor chip. The running buffer was
20mM HEPES–NaOH (pH 7.5), 200mM NaCl, 2.5%
glycerol, 1mM dithiothreitol and 0.1% Tween-20. For
the binding assay, 0.1mM TOPO IIIa, RPA, Topo I or
bovine serum albumin was injected for 2min.
Figure 1. EVL promotes the formation of circular ssDNA multimers.
(A) The ssDNA-binding assay. fX174 ssDNA (20mM) was incubated
with the EVL protein at 37C for 15min. The samples were then
separated by 0.8% agarose gel electrophoresis in TAE buffer and
were visualized by ethidium bromide staining. Lane 1 indicates a
negative control experiment without the protein. Lanes 2–6 indicate
the experiments with EVL. The concentrations of EVL were 0.1mM
(lane 2), 0.2mM (lane 3), 0.4mM (lane 4), 0.8mM (lane 5) and 1.6mM
(lane 6). The fX174 circular ssDNA molecule is indicated by css.
(B) Multimer formation. fX174 circular ssDNA (20mM) was incubated
with EVL. The samples were then separated by 1% agarose gel
electrophoresis and were visualized by SYBR Gold staining. The con-
centrations of EVL were 0.125mM (lane 2), 0.25mM (lane 3), 0.5mM
(lane 4), 1mM (lane 5) and 2mM (lanes 6 and 7). Lane 7 was incubated
at 100C for 5min. Lane 1 indicates a negative control experiment
without the protein. (C) Inhibition of ssDNA multimer formation by
RPA. fX174 circular ssDNA (20mM) was incubated with EVL (1mM)
in the presence or absence of RPA (2mM). (D) Inhibition of the
EVL-mediated ssDNA annealing by RPA. EVL (1mM) was ﬁrst
incubated with ssDNA (0.2mM) in the presence or absence of RPA
(80nM), followed by the addition of a complementary ssDNA. The
reactions were conducted at 30C for 8min.
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EVL promotes the formation of circular ssDNA multimers
As described earlier (2), EVL bound to fX174 circular
ssDNA (5386 bases) and formed large complexes
(Figure 1A). We found that ssDNA multimers were
formed within this EVL–ssDNA complex, after the EVL
protein was removed from the complex by an SDS and
proteinase K treatment (Figure 1B). Since we previously
reported that EVL promotes the annealing of complemen-
tary ssDNAs (2), we suspected that the ssDNA multimers
may be annealed products between short, complementary
sequences within the fX174 circular ssDNA. As
anticipated, the ssDNA multimers were dissociated into
monomers, when the samples were incubated at 100C
for 5min (Figure 1B, lane 7). In addition, the formation
of the ssDNA multimers by EVL was completely sup-
pressed by an ssDNA-binding protein, RPA
(Figure 1C), which signiﬁcantly inhibited the ssDNA an-
nealing by EVL (Figure 1D). Therefore, we concluded
that EVL promotes annealing between short, complemen-
tary sequences within the fX174 circular ssDNA and
forms ssDNA multimers.
EVL promotes ssDNA catenation in the presence
of Topo I
The ssDNA multimers formed by EVL may be annealed
products, because the multimers were dissociated by
heating (Figure 1B). Interestingly, we found that the
ssDNA multimers formed by EVL in the presence of a
type I topoisomerase, E. coli Topo I, were not resolved
after incubation at 100C for 5min (Figure 2A, lane 6).
These heat-stable ssDNA multimers may be ssDNA
catemers. To assess whether ssDNA catemers were
formed, we visualized the heat-stable ssDNA multimers
by electron microscopy. To do so, the ssDNA multimers
were puriﬁed, and were then coated with RecA to visualize
the ssDNA. As anticipated, circular ssDNA catemers,
containing two or three ssDNA molecules, were
observed (Figure 2B). We counted a total of 102 molecules
from the DNA samples and found that about 72.5, 18.6,
6.9 and 2% of ssDNA molecules were single circles, two
Figure 2. EVL promotes the ssDNA-catenating activity in the presence of Topo I. (A) Catemer formation. fX174 circular ssDNA (20mM) was
incubated with EVL (1mM) and Topo I (0.4nM). Lanes 1 and 2 indicate negative control experiments without the protein. Lanes 3 and 4 indicate the
experiments in the presence of EVL. Lanes 5 and 6 indicate the experiments in the presence of EVL and Topo I. Lanes 7 and 8 indicate the
experiments in the presence of Topo I. In the experiments shown in lanes 2, 4, 6 and 8, the samples were incubated at 100C for 5min before loading
on the gel. Lanes 1, 3, 5 and 7 indicate control experiments without the 100C incubation step. The fX174 circular ssDNA molecule is indicated by
css. (B) Electron microscopic visualization of the ssDNA catemers. Scale bars denote 100nm.
Figure 3. Catalytic function of Topo I in the EVL-mediated
ssDNA-catenating reaction. (A) fX174 circular ssDNA (20mM) was
incubated with Topo I in the presence of EVL. To eliminate the
annealed products, the reaction products were treated at 100C for
5min before loading on the gel. Lane 1 is a control experiment
without the proteins. Lane 2 indicates a negative control experiment
without Topo I in the presence of EVL (1mM). Lanes 3–6 indicate the
experiments with various amounts of Topo I in the presence of EVL
(1mM). The concentrations of Topo I are 0.04nM (lane 3), 0.2nM
(lane 4), 0.4nM (lane 5) and 0.8nM (lane 6). Lane 7 indicates a
negative control experiment with Topo I (0.8nM) in the absence of
EVL. The fX174 circular ssDNA molecule is indicated by css.
(B) fX174 superhelical dsDNA (20mM) was incubated with EVL
(1mM) and Topo I (0.4nM or 40nM). Lane 1 indicates the negative
control experiment without the protein. Lanes 2, 5 and 6 indicate the
experiments in the presence of EVL (1mM). Lanes 3 and 5 indicate the
experiments in the presence of a low amount of Topo I (0.4nM). Lanes
4 and 6 indicate the experiments in the presence of a high amount of
Topo I (40nM). fX174 superhelical and nicked or open circular
dsDNA molecules are indicated by sc and nc/oc, respectively.
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ssDNA catemers, respectively. Therefore, we concluded
that the heat-stable ssDNA multimers are ssDNA
catemers.
The ssDNA-catenating reaction did not occur when
either EVL or Topo I was omitted from the reaction
mixture (Figure 3A, lanes 2 and 7), indicating that both
EVL and Topo I are essential for the ssDNA-catenating
reaction. In addition, the formation of EVL-dependent
DNA catemers was not detected when circular dsDNA
was used as a substrate (Figure 3B). Protein titration ex-
periments revealed that a very small amount of Topo I
(0.04nM) was sufﬁcient to form the ssDNA catemers
(Figure 3A, lane 3). This Topo I concentration
(0.04nM) was far below the amount required for
inducing a topological change in supercoiled DNA,
because 0.4nM of Topo I is not sufﬁcient to relax super-
coiled DNA (Figure 3B, lanes 3 and 5). Therefore, these
results suggested that Topo I catalytically functions in the
EVL-dependent ssDNA-catenating reaction.
EVL-mediated ssDNA annealing plays an essential role
in the ssDNA-catenating reaction
We next tested whether the ssDNA annealing by EVL
plays an essential role in the ssDNA-catenating reaction
with Topo I. To do so, we prepared two EVL fragments,
EVL(1–221) and EVL(222–418), which contained amino
acid residues 1–221 and 222–418, respectively (7). As
shown in Figure 4A and B, EVL(222–418) promoted an-
nealing to a similar extent as full-length EVL, but
EVL(1–221) did not. We then tested whether
EVL(1–221) and EVL(222–418) support the ssDNA-
catenating reaction. As anticipated, EVL(222–418),
which possesses the annealing activity, promoted the
ssDNA-catenating reaction, with indistinguishable efﬁ-
ciency from the full-length EVL (Figure 4C, lane 7). In
contrast, EVL(1–221) did not promote the ssDNA-
catenating reaction (Figure 4C, lane 6). These results
indicated that the EVL annealing activity is essential for
the ssDNA-catenating reaction with Topo I.
Human TOPO IIIa catalyzes the ssDNA-catenating
reaction in the presence of EVL
We then determined whether human topoisomerase can
also promote the EVL-dependent ssDNA-catenating
reaction. A eukaryotic type I topoisomerase, human
TOPO IIIa, reportedly functions in homologous recom-
bination (11–18). Therefore, we puriﬁed human TOPO
IIIa as a recombinant protein (Figure 5A). The puriﬁed
TOPO IIIa was chemically conjugated to Afﬁ-Gel 10, and
pull-down assays were performed with MCF7 cell
extracts. As shown in Figure 5B (lane 3), the endogenous
EVL protein in the MCF7 cells was clearly detected in the
TOPO IIIa-bound fraction. A SPR analysis also revealed
that puriﬁed TOPO IIIa efﬁciently bound to EVL
(Figure 5C). We next performed the EVL-dependent
ssDNA-catenating assay with TOPO IIIa. As shown in
Figure 5D, TOPO IIIa signiﬁcantly stimulated the
ssDNA-catenating reaction in the presence of EVL. Like
E. coli Topo I (Figure 3A), the ssDNA catemers were
formed with a very small amount of TOPO IIIa
(0.01nM, Figure 5D, lane 4), suggesting its catalytic
function in the reaction. The ssDNA catemers were not
formed when either EVL or TOPO IIIa was omitted from
the reaction mixture (Figure 5D, lanes 2 and 8). In
addition, we found that the ssDNA-catenating reaction
mediated by EVL and TOPO IIIa was signiﬁcantly in-
hibited by RPA (Figure 6A), which suppresses the
EVL-dependent ssDNA annealing (Figure 1C and D).
The EVL-TOPO IIIa interaction was still observed in
the presence of RPA (Figure 6B). These results suggested
that RPA inhibits the ssDNA-catenating reaction by in-
hibiting the EVL-mediated ssDNA annealing.
Intriguingly, we also found that EVL bound to E. coli
Topo I, with reduced afﬁnity as compared to human
TOPO IIIa in vitro (Figure 5C). Although this
EVL-Topo I combination does not exist in the natural
context, it suggested that EVL binding to the Topo I
Figure 4. The EVH2 domain is responsible for the ssDNA-annealing
activity and the ssDNA-catenation. (A) ssDNA annealing activities of
EVL(222–418). EVL, EVL(1–221) or EVL(222–418) was ﬁrst incubated
with ssDNA (0.2mM), followed by the addition of a complementary
ssDNA. The reactions were conducted at 30C for 8min. Lane 1 indi-
cates a control experiment without protein, and lanes 2–4, lanes 5–7
and lanes 8–10 indicate the experiments with EVL, EVL(1–221) and
EVL(222–418), respectively. The EVL, EVL(1–221) and EVL(222–418)
concentrations were 0.1mM (lanes 2, 5 and 8), 0.5mM (lanes 3, 6 and 9)
and 1mM (lanes 4, 7 and 10). (B) Graphical representation of the ex-
periments shown in panel A. The band intensities of the annealed
products were quantiEed, and the average values of three independent
experiments are shown with the standard deviation values. Closed
circles, open circles and open triangles indicate experiments with
EVL, EVL(222–418) and EVL(1–221), respectively. (C) Catemer forma-
tion with the EVL(222–418) fragment. Lane 1 indicates a control ex-
periment without protein. Lanes 2 and 5 indicate the experiments with
EVL. Lanes 3 and 6 indicate the experiments with EVL(1–221). Lanes 4
and 7 indicate the experiments with EVL(222–418). Lanes 5–8 indicate
the experiments in the presence of Topo I (0.4nM). The fX174 circular
ssDNA molecule is indicated by css.
Nucleic Acids Research, 2010,Vol.38, No. 21 7583Figure 5. Human TOPO IIIa catalyzes the ssDNA-catenating reaction in the presence of EVL. (A) Human TOPO IIIa was puriﬁed and analyzed by
15% SDS–PAGE with Coomassie Brilliant Blue staining. (B) Pull down assay. Afﬁ-Gel 10 beads chemically conjugated with human TOPO IIIa were
incubated with MCF7 whole cell extract. Proteins bound to the TOPO IIIa beads were separated by SDS–PAGE and were analyzed by western
blotting. Endogenous EVL was probed with an anti-EVL polyclonal antibody. Lanes 2 and 3 indicate experiments with the control Afﬁ-Gel 10 beads
and the TOPO IIIa beads, respectively, in the presence of the MCF7 cell lysate. Lane 1 indicates a control experiment with the TOPO IIIa beads in
the absence of the MCF7 cell lysate. The input MCF7 cell lysate (20mg of protein) and the puriﬁed EVL (2ng) protein were applied in lanes 4 and 5,
respectively. (C) SPR analysis of the TOPO IIIa-EVL interaction. Sensorgrams for TOPO IIIa, Topo I and bovine serum albumin (BSA) binding to
the immobilized EVL protein are presented. (D) fX174 circular ssDNA (20mM) was incubated with TOPO IIIa in the presence of EVL. To eliminate
the annealed products, the reaction products were treated at 100C for 5min before loading on the gel. Lane 1 is a control experiment without the
proteins. Lane 2 indicates a negative control experiment without TOPO IIIa in the presence of EVL (1mM). Lanes 3–7 indicate the experiments with
various amounts of TOPO IIIa in the presence of EVL (1mM). The concentrations of TOPO IIIa are 0.001nM (lane 3), 0.01nM (lane 4), 0.05nM
(lane 5), 0.1nM (lane 6) and 0.5nM (lane 7). Lane 8 indicates a negative control experiment with TOPO IIIa (0.5nM) in the absence of EVL. The
fX174 circular ssDNA molecule is indicated by css.
Figure 6. RPA inhibits the ssDNA-catenating reaction mediated by EVL and human TOPO IIIa.( A) fX174 circular ssDNA (20mM) was incubated
with TOPO IIIa and EVL in the presence or absence of RPA. Lanes 1–8 indicate control experiments without boiling. Lanes 9 and 10 indicate the
ssDNA-catenating experiments, in which the reaction products were treated at 100C for 5min before loading on the gel. Proteins added to the reactions
are indicated on the top of panel A. Protein concentrations were RPA (2mM), EVL (1mM) and TOPO IIIa (0.1nM). (B) SPR analysis of the TOPO
IIIa–EVL interaction in the presence of RPA. Sensorgrams for TOPO IIIa/RPA and RPA binding to the immobilized EVL protein are presented.
7584 Nucleic Acids Research, 2010,Vol.38, No. 21region, which may be evolutionarily conserved with
TOPO IIIa, may enhance the ssDNA-catenating
reaction in vitro.
DISCUSSION
In the present study, we found that human EVL and a
type I topoisomerase promote the catenation of ssDNA
molecules. It has been reported that RecA, a bacterial re-
combinase, promotes hemicatenation between ssDNA and
dsDNA in the presence of Topo I (8); however, no report
for the ssDNA-catenating reaction has been published
thus far. We also conﬁrmed that both prokaryotic and
eukaryotic type I topoisomerases are functional for the
ssDNA catenation with EVL.
Type I topoisomerase promotes cutting and rejoining
reactions on a strand within dsDNA. In the present
study, we showed that the annealing activity of EVL
plays an essential role in the ssDNA-catenating reaction
with a type I topoisomerase. Therefore, we have proposed
an annealing-mediated model for the ssDNA-catenating
reaction (Figure 7). In this model, EVL ﬁrst binds to
ssDNA and forms large complexes, each containing
multiple ssDNA molecules (Step 1). Since human EVL
contains a tetramerization domain at its C-terminus (21),
the formation of multiple ssDNA complexes may be
mediated through its tetramerization activity. The short
complementary sequences of the ssDNA may be
annealed within the EVL-multiple ssDNA complexes
(Step 2). A type I topoisomerase, which may be recruited
on the ssDNA annealed sites through binding to EVL,
then cuts an ssDNA strand within the annealed region
(Step 3). This nicked site rotates and rejoins (Step 4).
The functional signiﬁcance of the ssDNA catenation by
EVL and topoisomerases remains to be elucidated;
however, it may be involved in homologous recombin-
ation because EVL directly interacts with the eukaryotic
RecA homologs, RAD51 and RAD51B (2). Our previous
analyses suggested that EVL may function as a RAD51
mediator, which stimulates the RAD51-mediated
homologous-pairing and strand-exchange reactions (2,7).
The ssDNA-catenating activity, comprising the ssDNA
cutting and rejoining reactions, may be utilized to
process the DNA intermediates formed by the
homologous-pairing and strand-exchange reactions by
RAD51. In the homologous-recombination process, it
has been proposed that a DNA intermediate containing
a D-loop, in which the ssDNA has invaded a homologous
region of the intact dsDNA, is ﬁrst formed by the
RAD51-mediated homologous pairing. After this
homologous-pairing step, the invading strand primes
repair synthesis of the DNA strands, and the D-loop
structure is converted to a four-way junction, the
Holliday-junction intermediate, which moves along the
DNA to expand the newly paired heteroduplex region.
The ssDNA cutting and rejoining activities of EVL and
topoisomerase may be involved in the conversion process
from the D-loop to Holliday junction intermediates.
Alternatively, the ssDNA cutting and rejoining
activities may function in the resolution of the Holliday
junction. The Holliday-junction intermediate must be
resolved into two parental DNA molecules by the
ssDNA-nicking activity in the late stage of the
homologous-recombination pathway. Interestingly,
human TOPO IIIa, which was found to promote the
ssDNA-catenating reaction with EVL, is reportedly
involved in Holliday junction dissolution (13–16). In
addition, EVL is known to bind RAD51B, which prefer-
entially binds to the Holliday junction (2,22). Therefore,
EVL may also be involved in the late stage of the HRR
pathway, together with TOPO IIIa. Further analyses are
required to clarify these issues.
Figure 7. Model for the ssDNA-catenating reaction by EVL and a
type I topoisomerase.
Nucleic Acids Research, 2010,Vol.38, No. 21 7585ACKNOWLEDGEMENT
H. K. is a research fellow in the Waseda Research Institute
for Science and Engineering.
FUNDING
Grants-in-Aid from the Ministry of Education, Culture,
Sports, Science and Technology (MEXT), and the
Japanese Society for the Promotion of Science (JSPS)
of Japan. Funding for open access charge: Waseda
University.
Conﬂict of interest statement. None declared.
REFERENCES
1. Kwiatkowski,A.V., Gertler,F.B. and Loureiro,J.J. (2003) Function
and regulation of Ena/VASP proteins. Trends Cell. Biol., 13,
386–392.
2. Takaku,M., Machida,S., Hosoya,N., Nakayama,S., Takizawa,Y.,
Sakane,I., Shibata,T., Miyagawa,K. and Kurumizaka,H. (2009)
Recombination activator function of the novel RAD51- and
RAD51B-binding protein, human EVL. J. Biol. Chem., 284,
14326–14336.
3. Symington,L.S. (2002) Role of RAD52 epistasis group genes in
homologous recombination and double-strand break repair.
Microbiol. Mol. Biol. Rev., 66, 630–670.
4. West,S.C. (2003) Molecular views of recombination proteins and
their control. Nat. Rev. Mol. Cell. Biol., 4, 435–445.
5. Sung,P., Krejci,L., Van Komen,S. and Sehorn,M.G. (2003) Rad51
recombinase and recombination mediators. J. Biol. Chem., 278,
42729–42732.
6. San Filippo,J., Sung,P. and Klein,H. (2008) Mechanism of
eukaryotic homologous recombination. Annu. Rev. Biochem., 77,
229–257.
7. Takaku,M., Machida,S., Nakayama,S., Takahashi,D. and
Kurumizaka,H. (2009) Biochemical analysis of the human EVL
domains in homologous recombination. FEBS J., 276, 5841–5848.
8. Cunningham,R.P., Wu,A.M., Shibata,T., DasGupta,C. and
Radding,C.M. (1981) Homologous pairing and topological linkage
of DNA molecules by combined action of E. coli RecA protein
and topoisomerase I. Cell, 24, 213–223.
9. Harmon,F.G., DiGate,R.J. and Kowalczykowski,S.C. (1999)
RecQ helicase and topoisomerase III comprise a novel DNA
strand passage function: a conserved mechanism for control of
DNA recombination. Mol. Cell, 3, 611–620.
10. Harmon,F.G., Brockman,J.P. and Kowalczykowski,S.C. (2003)
RecQ helicase stimulates both DNA catenation and changes in
DNA topology by topoisomerase III. J. Biol. Chem., 278,
42668–42678.
11. Wu,L., Davies,S.L., North,P.S., Goulaouic,H., Riou,J.F.,
Turley,H., Gatter,K.C. and Hickson,I.D. (2000) The Bloom’s
syndrome gene product interacts with topoisomerase III.
J. Biol. Chem., 275, 9636–9644.
12. Cheok,C.F., Bachrati,C.Z., Chan,K.L., Ralf,C., Wu,L. and
Hickson,I.D. (2005) Roles of the Bloom’s syndrome helicase in
the maintenance of genome stability. Biochem. Soc. Trans., 33,
1456–1459.
13. Wu,L. and Hickson,I.D. (2003) The Bloom’s syndrome helicase
suppresses crossing over during homologous recombination.
Nature, 426, 870–874.
14. Wu,L., Bachrati,C.Z., Ou,J., Xu,C., Yin,J., Chang,M., Wang,W.,
Li,L., Brown,G.W. and Hickson,I.D. (2006) BLAP75/RMI1
promotes the BLM-dependent dissolution of homologous
recombination intermediates. Proc. Natl Acad. Sci. USA, 103,
4068–4073.
15. Raynard,S., Bussen,W. and Sung,P. (2006) A double Holliday
junction dissolvasome comprising BLM, topoisomerase IIIalpha,
and BLAP75. J. Biol. Chem., 281, 13861–13864.
16. Bussen,W., Raynard,S., Busygina,V., Singh,A.K. and Sung,P.
(2007) Holliday junction processing activity of the BLM-Topo
IIIalpha-BLAP75 complex. J. Biol. Chem., 282, 31484–31492.
17. Raynard,S., Zhao,W., Bussen,W., Lu,L., Ding,Y.Y., Busygina,V.,
Meetei,A.R. and Sung,P. (2008) Functional role of BLAP75 in
BLM-topoisomerase IIIalpha-dependent holliday junction
processing. J. Biol. Chem., 283, 15701–15708.
18. Singh,T.R., Ali,A.M., Busygina,V., Raynard,S., Fan,Q., Du,C.H.,
Andreassen,P.R., Sung,P. and Meetei,A.R. (2008) BLAP18/RMI2,
a novel OB-fold-containing protein, is an essential component of
the Bloom helicase-double Holliday junction dissolvasome.
Genes Dev., 22, 2856–2868.
19. Henricksen,L.A., Umbricht,C.B. and Wold,M.S. (1994)
Recombinant replication protein A: expression, complex
formation, and functional characterization. J. Biol. Chem., 269,
11121–11132.
20. Bradford,M.M. (1976) A rapid and sensitive method for the
quantitation of microgram quantities of protein utilizing the
principle of protein-dye binding. Anal. Biochem., 72, 248–254.
21. Bachmann,C., Fischer,L., Walter,U. and Reinhard,M. (1999) The
EVH2 domain of the vasodilator-stimulated phosphoprotein
mediates tetramerization, F-actin binding, and actin bundle
formation. J. Biol. Chem., 274, 23549–23557.
22. Yokoyama,H., Kurumizaka,H., Ikawa,S., Yokoyama,S. and
Shibata,T. (2003) Holliday junction binding activity of the human
Rad51B protein. J. Biol. Chem., 278, 2767–2772.
7586 Nucleic Acids Research, 2010,Vol.38, No. 21